Tiburio Therapeutics
Pioneering therapies that target rare neuroendocrine tumors and endocrine diseases for a brighter, healthier future.
Pioneering therapies that target rare neuroendocrine tumors and endocrine diseases for a brighter, healthier future.
Tiburio Therapeutics is a biotechnology startup established in 2018 with a mission to pioneer therapies targeting rare neuroendocrine tumors and endocrine diseases for a brighter, healthier future. The company's innovative drug compounds are designed to address the treatment of tumors and endocrine diseases, particularly non-functioning pituitary adenomas. These compounds leverage a dopamine-somatostatin chimeric molecule to potentially shrink or halt tumor growth, providing patients with effective treatment options for these rare conditions.
The startup recently secured a significant $31.00M Series A investment on 03 January 2019. The investors participating in this round include prominent names such as New Enterprise Associates, Longitude Capital, Alexandria Venture Investments, and Lundbeckfonden Ventures.
Overall, Tiburio Therapeutics stands at the forefront of biotechnological advancements in healthcare and pharmaceuticals, aiming to make a tangible difference in addressing rare and challenging medical conditions.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series A | $31.00M | 4 |
|
03 Jan 2019 |
No recent news or press coverage available for Tiburio Therapeutics.
We care about your data, and we'd love to use cookies make your experience better.